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Abstract. We have investigated the roles of pp60-src
and p21- proteins in transducing the nerve growth
factor (NGF) and fibroblast growth factor (FGF) sig-
nals which promote the sympathetic neuronlike pheno-
type in PC12 cells. Neutralizing antibodies directed
against either Src or Ras proteins were microinjected
into fused PC12 cells. Each antibody both prevented
and reversed NGF- or FGF-induced neurite growth, a
prominent morphological marker for the neuronal phe-
notype. These data demonstrate the involvement of
both pp60-- and p21-- proteins in NGF and FGF
actions in PC12 cells, and establish a physiological
role for the pp60c-s- tyrosine kinase in signal transduc-
tion pathways initiated by receptor tyrosine kinases in
these cells. Additional microinjection experiments,
N
ERVE growth factor (NGF)l (39) and fibroblast
growth factor (FGF) (for review see reference 70)
are neuronal growth factors which mediate survival
and differentiation ofmany typesofneurons in vivo and in pri-
mary neuronal cultures. Application ofNGF or FGF to cells
ofthe clonal rat pheochromocytoma cell line, PC12, engages
a program ofphysiological changes, resulting in a phenotype
resembling that of sympathetic neurons. These changes in-
clude neurite outgrowth,establishment ofa sodium-based ac-
tion potential, induction of a variety ofbiochemically defined
neuronal characteristics, and the cessation of cell division
(see reference 18) . The PC12 cell line has thus been a useful
model system for studying the intracellular events associated
with growth factor-induced neuronal differentiation.
The signal transduction pathways used by NGF to accom-
plish these changes have been extensively studied but are
only partially understood. Underlying the physiological
changes brought about by NGF and FGF is a coordinated se-
quence of posttranslational modifications and changes in
gene expression that occur throughout persistent treatment
with the growth factor (for review see reference 23). Several
1. Abbreviations used in this paper: FGF, fibroblast growth factor; GAP,
GTPase activating protein; MMTV, mouse mammary tumor virus; NGF,
nerve growth factor.
© The Rockefeller University Press, 0021-9525/91/11/809/11 $2.00
TheJournalofCell Biology, Volume 115, Number 3, November 1991809-819
using PC12 transfectants containing inducible v-src or
ras oncogene activities, demonstrated a specific se-
quence of Src and Ras actions. Microinjection of anti-
Ras antibody blocked v-src-induced neurite growth,
but microinjection of anti-Src antibodies had no effect
on ras oncogene-induced neurite growth. We propose
that a cascade of Src and Ras actions, with Src acting
first, is a significant feature of the signal transduction
pathways for NGF and FGF The Src-Ras cascade may
define a functional cassette in the signal transduction
pathways used by growth factors and other ligands
whose receptors have diverse structures and whose
range of actions on various cell types include mito-
genesis and differentiation.
second messenger pathways have been implicated in NGF
action including those which lead to protein phosphoryla-
tions (23) via activations of kinases including A-kinase and
C-kinase (9, 25) . NGF has also been shown to causea rapid
increase in the phosphorylation of several proteins on tyro-
sine (42). However, the signal-transducing molecules re-
sponsible for second messenger generation and the relation-
ships between these second messengers and the long-term
actions of NGF such as neurite outgrowth have not been well
established. Although FGF has actions on PC12 cells very
similar to those of NGF (56, 66, 67), its transduction path-
ways have only recently been a subject of study.
Recent evidence has implicated both src and ras proto-
oncogene activities in the NGF signal transduction pathway
leading to neurite growth . The ras gene products are GTP-
binding proteins that play critical roles in growth regulation
(for review see reference 4) . Activated, mutant Ras proteins,
that stimulate mitogenesis and oncogenic transformation in
many cell types, mimic a number ofneuronal growth factor
actions in PC12 cells, including induction of neurite out-
growth (3, 50) . Furthermore, microinjection of a neutraliz-
ing mAb to Ras into fused PC12 cells prevents and reverses
neurite outgrowth induced by NGF (21), and expression of
a dominant inhibitory ras mutant in PC12 cells blocks sev-
eral of the effects of NGF and FGF (64). The c-src gene
809product, pp60`- , belongs to a family of protein tyrosine
kinases, whosemembers have proposed roles in signal trans-
duction of receptor-regulated physiological processes (see
reference 5) . A potential role for pp60c-src or other tyrosine
kinase(s) in NGF signal transduction was suggested by the
ability of viral, oncogenic Src to mimic NGF-induced neu-
rite outgrowth (1) . Furthermore, NGF and pp60-- rapidly
stimulate tyrosine phosphorylations ofcommon protein sub-
strates (65) . Recent evidence suggests that the functional
NGF receptor includes both a previously identified 75ÁD
NGF-binding protein (27, 53), as well as the trk proto-on-
cogene tyrosine kinase (26, 31, 32) . TheFGF receptor also
possesses tyrosine kinase activity (38), further suggesting a
tyrosine kinase pathway in neuronal growth factor action .
The roles and relationships between src and ras products
have been partially addressed with respect to growth control
and oncogenesis in fibroblastic cells . Mitogenesis stimulated
by growth factors or by v-src is blocked by microinjected
anti-Ras (49, 61), or by expression of a dominant inhibitory
ras mutant (7) in NIH 3T3 cells . This suggests that p21°-ros
action is essential to the actions of some tyrosine kinases,
but it was not determined whether the tyrosine kinase and
p2l- act in parallel or in series .
Studies in PC12 cells and fibroblastic cell lines indicate
striking similarities between the roles of Src and Ras in the
control of neuronal differentiation and of mitogenesis . To
further elucidate the role of the src and ras proto-oncogenes
in neuronal growth factor action,we have examined the abil-
ity of microinjected anti-Src and anti-Ras to inhibit NGF-
and FGF-induced neurite outgrowth from fused PC12 cells .
These antibodies were also used to determine the functional
relationship between Src and Ras proteins by examining their
ability to inhibit oncogene-directed neurite growth after
microinjection intoPC12 sublines expressing inducible v-src
or ras oncogene products .
Materials and Methods
Cell Cultureand Fusion
PC12 cells (17), and PC12-derived subclones, were grown in DME (69)
containing 10% horse serum and 5% FCS (JRH, Lenexa, KS), at 37°C in
an atmosphere of 10% C02, 90% air . PC12 cells or subclones were fused
while attached to tissue culture dishes (51), fractionated on a 10 to 30%
serum gradient, andreplated at low density on glass cover slips coated with
laminin and poly-lysine, as described (22) . For the GSrasl line (see below),
one day before fusion, the growth medium was changed to one containing
serum which had been treated with activated charcoal to remove endoge-
nous glucocorticoids . NGF (2 .5 S ; 46) was added, where indicated, to the
cultures at 50 ng/ml . Recombinant bovine basic FGF (kindly supplied by
Dr. A . Baird, Whittier Institute, La Jolla, CA) was used, where indicated,
at 10 ng/ml with replenishment every two days . Dexamethasone (Sigma
Chemical Co ., St . Louis, MO) was dissolved in DMSO, and was added to
cultures, at the concentrations indicated . The final concentration ofDMSO
did not exceed 0.1% of the culture volume, and this DMSO level had no
effect on NGF-induced neurite outgrowth . The ts:v-src3 cells were main-
tained at 39.5°C, and the cells were shifted to the permissive temperature
of 35°C, where indicated, by moving the cultures to a separate incubator.
Generation ofPC12 Sublines
GSrasl cells were isolated by cotransfection of PC12 cells with two plas-
mids : pMJC25 and pRSVneo, using a Bio-Rad Gene Pulser (Bio-Rad
Laboratories, Richmond, CA) . The plasmid, pMJC25 (the gift ofM . Cor-
bley and T. Roberts, Dana Farber Cancer Institute, Boston, MA), contains
a mutated, human c-Ha-ras-1 gene (encoding p2lL6 ', a p21 with leucine at
position 61 ; see reference 10), under control ofthe mouse mammary tumor
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virus (MMTV) promoter. Theplasmid, pRSVneo, contains the gene encod-
ing neomycin resistance, under control of Rous Sarcoma Virus long termi-
nal repeat sequences (16) . Electroporation of4 x 106 cells was carried out
in 0.4 ml DME containing 18 kg pMJC25 and2,ug pRSVneo, using settings
of 300 V and 500 kF. Two days after transfection, cells were subjected to
G419 (Geneticin®; Gibco Laboratories, Grand Island, NY; 800 jig/ml) se-
lection . The selective medium was renewed every two days . After two
weeks, resistantcolonies were picked. Clones were screened for dexameth-
asone-induced neurite outgrowth, and one such clone, designated GSrasl,
was used in the present studies.
PC12 cells containing a dominant inhibitory ras mutant product, p21"'7
(13), was generated as above, by cotransfecting pRSVneo, and a second con-
struct, pMMRasDN, containing the ras mutant gene under control of the
MMTV promoter (constructed using vector sequences of pMM42K, ob-
tained from K . Wood, Dana Farber Cancer Institute) and the entire coding
sequence of p21"'7 (obtained from L . Feig, Tufts Medical School, Boston,
MA) . Clones were screened for the ability of dexamethasone to induce
p21N" transcripts and to block NGF-induced neurite growth . One such
clone, designated GSrasDN13, was used in the present studies .
The isolation and characterization ofthe ts:v-src3 cells is described else-
where (65) . PC12 cells were infected with a replication-defective murine
leukemia virus containing murine leukemia virus long terminal repeat se-
quences directing transcription of the neomycin resistance gene, and the
SV-40 early region promoter driving the ts:v-src gene cloned from Rous
Sarcoma Virus strain NY72-4, which exhibits temperature-sensitive tyro-
sine kinase and transforming activity (28, 43) . Infected cells were main-
tained at 39.5°C, selected with G418, cloned, and screened for neurite out-
growth at the permissive temperature of 35°C .
A PC12 subline expressing avian pp60`-5 r`+ was obtained followed infec-
tion with a recombinant murine leukemia retrovirus, LNCXc-src+, carry-
ing the avian c-src+ gene (40) underthe transcriptional control of the cyto-
megalovirus early promoter (45) . Infected cells were selected with G418,
cloned and screened for expression ofpp60-r' kinase activity, using anti-
bodies specific for chicken Src proteins . One such clone, csrc+3, which ex-
pressed the highest level of pp60"', was used in the present studies .
Antibody Preparation
All antibodies were stored at -20°C at 1-5 mg/ml in PBS (137 MM NaC1,
2 .7 mM KCI, 8.06 mM Na2HP04, 1.47 mM KH2P04) . Before microinjec-
tion, concentration and buffer exchange to 0.5 x PBS (68 .6mM NaCl, 1.35
mM KCI, 4.03 mM Na2HPO4, 0.74 mM KH2PO4), was performed with a
Centricon 30 ultrafilter (Amicon, Danvers, MA) . The final concentrations
of antibodies used for microinjection was : anti-Src 327 (ascites-derived),
8-10 mg/ml ; anti-Src 327 (hybridoma derived), 12 mg/ml ; anti-Src (2-17),
13 mg/ml ; anti-Ras Y13-259, 10-12 mg/ml ; control antibodies, 12 mg/ml .
Control antibodies were immunoglobulins purified from non-immune
rabbit serum by protein A-agarose affinity chromatography (Immunopure
kit ; Pierce Chemical Co ., Rockford, IL), and dialysis against PBS. Mono-
clonal anti-Ras Y13-259 was obtained from the serum-free supernatant of
rat hybridoma cells (kindly provided by Dr . E . Scolnick, Merck and Co .,
Rahway, NJ), and purified by precipitation from 50% ammonium sulfate,
and protein-A agarose chromatography, followed by dialysis against PBS.
After ultrafiltration, 50-Al aliquotsat 10 mg/ml were storedat4°C. Concen-
trated Y13-259 consistently precipitated afterseveral weeks ofsuch storage,
so each aliquot of antibody was tested for its ability to block NGF-induced
neurite outgrowth immediately before its use in other experiments.
Monoclonal anti-Src 327 was prepared from mouse ascites fluid or from
the serum-free supernatant of hybridoma cells . It was precipitated from
50% ammonium sulfate, dialyzed against20mM Tris-HCI, pH 7.9, 40mM
NaCl, and fractionated on DEAE-Sephacel or by high performance chro-
matography using a DEAE-5PW column (Waters Chromatography, Mil-
ford, MA) eluted with a 30-500 mM NaCI gradient, and stored at -20°C
at N5 mg/ml . Buffer exchange and concentration to 8-10 mg/n-d were done
as above . Anti-Src 327 appeared to be very stable when stored at this con-
centration at 4°C . However, the degree ofinhibitory activity of each prepa-
ration ofanti-Src 327 varied . Differences in the inhibitory activity appeared
to correlate with differences in the titer of the antibody when assayed by
immunoprecipitation of pp60` -" . Furthermore, an anti-Src 327 prepara-
tion that was purified by elution from protein Aagarose with denaturants
was inactive in inhibiting neurite outgrowth, immunoprecipitated 5-10-fold
less pp60`-s
' than the preparations fractionated by ion exchange chroma-
tography, and was relatively unstable when stored at 4°C . As above, each
aliquot of327 was tested for its ability to inhibit NGF-induced neurite out-
growth just before its use in other experiments .
810Anti-Src (2-17) was prepared in the same manner as anti-Src 327 (see
above), by ammonium sulfate precipitation and ion exchange chromatogra-
phy of ascites fluid obtained from mice injected with hybridoma LA074
cells from Microbiological Associates (Rockville, MD).
Microinjection
Microinjection was performed using glass micropipettes containing a fila-
ment for back filling, and a micromanipulator (Wild Leitz, Rockleigh, NJ).
Cells in growth medium were injected at room temperature, and the pH of
the medium was held roughly constant by passing a gentle stream of COZ
over the culture dish. Every cell in a marked regionof the culture dish could
be microinjected by using the XY controls of the microscope stage to scan
the dish in a raster pattern. Weestimate that theinjection volume was -10%
of the cell's volume.
Results
SrcRequirementforNGFAction
To facilitate antibody microinjection, PC12 cells were fused
to form multinucleated giant cells. NGF rapidly initiates
neurite growth in the fused cells (22 ; and Fig. 1) . Fused cells
are readily microinjected and retain viability and respon-
siveness to growth factors after microinjection of non-
specific control antibodies. However, microinjection of the
neutralizing anti-Ras Y13-259 prevents and reverses NGF-
induced neurite outgrowth of these cells (21) .
The same experimental paradigm was used to determine
whether pp60-rc is essential for the induction of neurite
outgrowth by neuronal growth factors. In the experiments
shown in Fig. 1, we examined the effects of microinjection
of fused PC12 cells with monoclonal anti-Src 327 (41). This
antibody was selected for our study because microinjection
of anti-Src 327 into BALB/c-3T3 cells expressing a temper-
ature-sensitive mutant of pp60°-5"° inhibited the induction of
DNA synthesis in serum-free quiescent cultures shifted to
the permissivetemperature (P. Walton, J. Brugge, and J. Fer-
amisco, unpublished data).
To quantitate neurite outgrowth, the number of neurite-
bearing cells was counted in each set of microinjected cells.
Control cells were either injected with purified non-specific
immunoglobulins, or left uninjected. Monoclonal anti-Ras
Y13-259 injections were performed as a reference standard.
The results from three representative experiments are shown
in Fig. 1 . Injection ofnon-specific antibodies had little effect
on the viability, or NGF responsiveness of the fused cells
and, as previously reported, anti-Ras Y13-259 caused a sub-
stantial reduction in the number of NGF-induced neurites.
In each experiment, microinjection of anti-Src 327 inhibited
NGF-induced extension of neurites. Since the fraction of
neurite-bearing cells in the control NGF-treated cells varied
somewhat in each fused cell preparation, we defined an inhi-
bition index, I = 1 - P,/P., where P, is the percentage of
cells bearing neurites in cells after growth factor treatment
and injection with the test antibody, and Pc is the percent-
age of cells bearing neurites after growth factor treatment
and injection with control antibody. In the three experiments
shown in Fig. 1, microinjection of anti-Src caused a 67 to
77 % inhibition of neurite growth, in a total of 974 cells in-
jected with anti-Src 327 and 1,018 cells injected with control
antibody. In three additional experiments (not shown),
microinjection of anti-Src caused a 49 to 70% inhibition of
neurite outgrowth, with an average of 62% inhibition
(weighted average based on the number of cells injected in
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each experiment, with a total of 361 anti-Src-injected cells
and 286 control antibody-injected cells) . Under conditions
where the cells were pretreated with NGF for periods
sufficientto allow neurite outgrowth before microinjection,
the neurites retracted in response to microinjection of anti-
Src 327. For example, in comparing the experiments shown
in Fig. 1, a similar degree of inhibition was seen whether
NGF application preceded, or essentially coincided with an-
tibody microinjection. This result suggests that Src action is
continuously required for NGF-mediated neurite outgrowth,
in the same way that NGF is continually required to elicit
neurite outgrowth (17).
Several different preparations of anti-Src 327 (purified
from mouse ascites, or from serum-freehybridoma medium)
were effective in inhibiting neurite outgrowth induced by
NGF, suggesting that the observed inhibition of neurite
growth is not because of an impurity in the anti-Src 327 re-
agent. A second preparation of ascites-derived anti-Src 327
yielded 58% inhibition (78 anti-Src-injected cells and 81
control antibody-injected cells), and anti-Src 327 isolated
from serum-free hybridoma culture medium gave 47% in-
hibition (172 anti-Src-injected cells and 88 control anti-
body-injected cells) . To further ensure that the effects of anti-
Src 327 were because of its specific ability to interact with
Src protein, the antibody was microinjected into cells of a
PC12 subline, c-src+3, which express pp60c,rc+, the neu-
ronal c-src variant (see Materials and Methods; 40) at levels
10- to 20-fold greater than the endogenous pp60- level
(unpublished data) . In these cells, ascites-derived anti-Src
327 failed to inhibit NGF-induced neurite growth (an appar-
ent slight increase of 11% in neurite growth, based on 267
anti-Src 327-injected cells and 464 control antibody-injected
cells).
To further establish the role of pp60-, we performed ad-
ditional microinjection experiments with a second mAb, anti-
Src (2-17), (see Materials and Methods), raised against a
synthetic peptide corresponding to the unique amino terminus
of pp60c-s- (amino acid residues 2-17). In six experiments,
using a total of 2,604 microinjected cells (2,076 anti-Src-
injected and 528 control antibody-injected), microinjection
of fused PC12 cellswith anti-Src (2-17) caused inhibition of
NGF-induced neurite outgrowth ranging from 46 to 92%,
with an average inhibition of 65 % (weighted average calcu-
lated as above) . Thus, the inhibition induced by this antibody
is similar to that obtained using anti-Src 327.
The inhibitory effects of anti-Src 327 microinjection were
reversible. Inhibition ofNGF-induced neurites was maximal
24 h after injection and decayed by 60 h. The transient nature
of the inhibitory effects of microinjected antibodies is likely
because of intracellular degradation of the antibodies (49,
71), and further indicates that the inhibition of neurite
growth is not because of a toxic effect of the injected anti-
body. Furthermore, the anti-Src 327 only slightly inhibited
the transient and robust (98 % of cells) outgrowth of neurite-
like processes induced by 1 mM dibutyryl cAMP treatment
(59) of fused PC12 cells (inhibition index = 20%, based on
a total of 317 anti-Src-injected cells and 341 control
antibody-injected cells).
CascadeofSrc andRasActions
The above results suggest that pp60,,- as well as a ras gene
product are essential components ofan NGF signal transduc-The Journal of Cell Biology, Volume 115, 1991
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812tion pathway for neurite growth . To determine whether the
Src and the Ras components are acting in parallel or in se-
quence, we generated clonal PC12 cell sublines expressing
inducible Src or Ras transforming proteins . In similar cell
lines, neurite growth can be induced by pp60-- (54) or the
oncogenic Ras protein (63) in the absence of growth factor
receptor activation . The PC12-derived ts:v-src3 cell line
contains a mutant v-src gene expressing a temperature-sen-
sitive v-src kinase (65) . The ts:v-src3 cells express pp60,-s-
at a level approximately equal to endogenous pp60-- in
PC12 cells (unpublished data) . Shifting these cells from the
maintenance temperature of 39.5°C to the permissive tem-
perature of 35°C caused formation of neurites under the
direction of the ts:v-src kinase . In fused ts :v-src3 cells, neu-
rite outgrowth was observed within 24 h after downshift . An-
other PC12 clone, GSrasl, expressed the mutant c-ras on-
cogene product p2 1L6 ', under the transcriptional control of
the glucocorticoid-inducible MMTV promoter (see Materials
and Methods) . Treatment of these cells with dexamethasone
for 24 h caused an increase in p21 L61 transcription (data
not shown) and in neurite outgrowth, as was reported for a
similar cell line (63) . GSrasl cells retained these properties
after fusion . As expected, dexamethasone treatment of pa-
rental PC12 cells (fused or unfused) did not elicit neurite
outgrowth (18) .
To determine if pp60,s- required p21 eras to elicit neurite
growth, anti-Ras Y13-259 was injected into fused ts:v-src3
cells before temperature downshift . As seen in Fig . 2,
microinjection of anti-Ras Y13-259 inhibited pp60--
induced neurite outgrowth at the permissive temperature . In
results from three separate experiments including 563
microinjected cells, neurite outgrowth was inhibited 62 to
86% by microinjection of anti-Ras Y13-259 . Microinjection
of control non-specific antibody had no effect on neurite out-
growth after temperature downshift. These data suggested
that at least one member of the p2l-ros protein family is es-
sential for pp60°--induced neurite growth . In an alterna-
tive approach to investigate the role of Ras proteins in
pp60"-s- action, a PC12 cell subline containing a dominant
inhibitory mutant ras gene, p21"" (13) under transcrip-
tional control of theMMTV promoter, was established (see
Materials and Methods) . In this subline, GSrasDN13,
dexamethasone-induced expression of p21N inhibited neu-
rite outgrowth induced by NGF, as seen in a similar PC12
subline (64) . Infection of GSrasDN13 cells or PC12 cells
with a v-src-containing retrovirus resulted in neurite growth
(thenumber of neurites in a 60-mm tissue culture dish was
counted) . Treatment ofGSrasDN13 cells with 0.5 pM dexa-
methasone, 2 d after infection, reduced the number of neu-
rites by 85% (infection only, 806 neurites ; infection and
dexamethasone, 120 neurites), whereas dexamethasone treat-
ment of infected PC12 cells reduced the number of neurites
by only 3% (infection only, 648 neurites ; infection and dexa-
methasone, 626 neurites) . The above results indicate that
Ras proteins may be acting either downstream of pp60°-Src,
or in a parallel pathway that is required for neurite out-
growth .
To further elucidate the relationship between the roles of
Src and Ras in neurite outgrowth, experiments were per-
formed with the GSrasl cell line, in which dexamethasone
is used to induce neurites under the direction of p2lL61 .
Anti-Src 327 microinjection did not reduce the number of
GSrasl cells bearing neurites after treatment with dexameth-
asone, as indicated by the three experiments shown in Fig. 3 .
As would be expected however, microinjection of anti-Ras
Y13-259 inhibited neurite outgrowth (65 and 57% inhibi-
tion, for two experiments shown in Fig . 3) resulting from
dexamethasone treatment . This result suggests that pp60`- s-
is not required for the induction of neurites by p21L6' . To
ensure that generation of the GSrasl cell line did not dis-
rupt the NGF signalling pathway which requires pp60`-,-
and p2l'ros proteins, GSrasl cells were also treated with
NGF. Fused GSrasl cells produced neurites in response to
NGF, and microinjection of anti-Src 327 or anti-Ras Y13-
259 inhibited NGF-induced neurite growth in these cells
(Fig . 3, inset) . It was also possible that p2lL6' resulted in a
more aggressive activation of pp60-s- which could not be
significantly inhibited by microinjected anti-Src 327. To con-
trol for this possibility, fused ts:v-src3 cells, in which all
pp60"- s- molecules are highly activated, were injected with
anti-Src 327. This resulted in a 52% inhibition of neurite
growth after temperature downshift (derived from 306 anti-
Src 327-injected cells, and 322 control antibody-injected
cells) . All of the above data indicate that although p21- is
essential for pp60---induced neurite outgrowth, the con-
verse is not true . The Src requirement in neurite growth was
bypassed by the expression of the p21L6 ' protein .
Requirements ofSrcandRas in FGFAction
Our results suggest that both Src and Ras proteins are re-
quired for the induction of neurites by NGR FGF is a neu-
ronal growth factor whose receptor is a tyrosine kinase (38) .
PC12 cells expressflg, but not bek, transcripts (DArcangelo,
G ., andC . Dionne, unpublished data) and FGF induces pro-
tein phosphorylation on tyrosines in these cells (Thomas, S .,
Figure 1. Inhibition of NGF-induced neurite outgrowth by microinjection of anti-Src 327 and anti-Ras Y13-259 . PC12 cells were fused,
treated with a saturating amount ofNGF (50 ng/ml), microinjected, and incubated to allow neurite outgrowth,all as described in Materials
and Methods . Cells were then scored for neurite outgrowth . A cell was considered to have neurites if it hadone or more processes extending
one or more cell body diameters (at least 50 Am) from the cell's periphery and with prominent growth cone(s) . The results obtained from
independent cell fusions are shown separately, indicated by solid, hatched, and open bars . The NGF-treated cells were either not injected
(none), injected with control antibodies (control), injected with anti-Src 327 (anti-src), or injected with anti-Ras Y13-259 (anti-ras) . Each
bar plots the percentage ofcells with neurites after NGF treatment, microinjection, and incubation . Above each bar is the number ofcells
counted for each particular treatment . In the first experiment (solid bars) NGF was applied 6 h before microinjection ; no neurite outgrowth
was observed at this early time . Cells were scored for neurites 24 h after microinjection . In the second and third experiments (®, 0, re-
spectively), NGF application for 20-22 h caused neurite outgrowth by the time of microinjection, and the cells were scored for neurites
23-26 h after microinjection . The photomicrographs show fused PC12 cells which have been treated with NGF, microinjected (or not)
with the indicated antibodies and incubated . The photomicrographs were taken at the time of scoring the cells for neurites .
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813Figure 2 . Inhibition of pp60-rc-induced neurite outgrowth by microinjection of anti-Ras Y13-259 into fused ts:v-src3 cells . Cells were
fused, microinjected, andscored for neurite outgrowth as in Fig . 1 .The results ofthree separate experiments are indicatedby solid, hatched,
and open bars . Each bar plots the percentage of cells bearing neurites aftereach treatment, with the total number of cells counted shown
above each bar. The ts:v-src3 cells were fused and maintained at 39.5°C until the time of microinjection . The cells were microinjected
at room temperature withcontrol antibodies (control) orwith anti-Ras Y13-259 (anti-ras), andthents:v-src activity was continually induced
by incubating the cells at 35°C. The cells were scored for neurites 24 h later. The photomicrographs, made at the time of scoring the
cells for neurites, are of typical ts:v-src3 cells after microinjection of the indicated antibodies .
Figure 3 . Lack of inhibition of p21L 6'-induced neurites by microinjection of anti-Src 327 into fused GSrasl cells. Cells were fused,
microinjected andscored for neurite outgrowth as in Fig . 1 . The results from three independent experiments are indicated by solid, hatched,
andopen bars. Each bar plots the percentage of cells bearing neurites after each treatment, andthe totalnumber ofcells counted is shown
above each bar. In each experiment, GSrasl cells were fused, maintained in glucocorticoid-freemedium,then treated with dexamethasone
to induce MMTVp21L 6' . GSrasl cells were either not injected (none), injected with control antibodies (control), injected with anti-Src
327 (anti-src), or injected withanti-Ras Y13-259 (anti-ras) .The antibodies were fromthesame preparations, and at thesame concentrations
as in Fig . 1 . In the first experiment with GSrasl cells (/ ), the cells were treated with 100 nM dexamethasone for 5 h, microinjected and
then incubated with the same medium and scored for neurites 30 h later. In the second experiment (®), 100nM dexamethasone wasadded
at the time of microinjection, and the cells were scored after24 h . In the third experiment ([]), 300 nM dexamethasone was added 7 h
before microinjection, and the cells were scored 25 h later. Thephotomicrographs were taken at the time of scoring the cells for neurites .
(Inset) An experiment wasperformed to determine whether the NGF signaling pathway in GSrasl cells was the same as in PC12 cells .
Neurite outgrowth was induced by NGF rather than dexamethasone . The cells were treated with NGF for 4 h, microinjected, and then
scored for neurites after an additional 24 h .
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and J. Brugge, unpublished data) . To examine whether neu-
rite outgrowth elicited by FGF is dependent on Src and Ras,
we performed additional microinjection experiments with
fused PC12 cells. As shown in Fig. 4, microinjection of anti-
Src 327 caused a 56% inhibition (439 microinjected cells,
Fig. 4 A) in the ability of bFGF to elicit neurites. Similarly,
microinjection of anti-Ras Y13-259 into fused PC12 cells
caused a 66% inhibition of neurite outgrowth (522 microin-
jected cells, Fig. 4 B) . Control non-specific antibody injec-
tion did not causea significant change in the number of cells
bearing neurites after bFGF treatment. As in the NGF-
treated fused PC12 cells, antibodies to Src or Ras protein
caused retraction of previously formed neurites under condi-
tions where the microinjection was delayed until FGF-
induced neurites were elaborated (data not shown) . The
above results suggest that the action of bFGF, like that of
NGF, involves a signal transductionpathway that requires the
continual activity of both Src and Ras proteins.
Microinjection of antibodies into living cells has been an
effective approach for identifying essential components in the
pathways used by growth factors and oneogenes (14, 49, 61) .
We exploited this approach to define the roles of the src and
ras proto-oncogene products and to determine their func-
tional relationships in the signal transduction pathways used
by growth factors such as NGF and FGF Our assay for these
growth factor actions has been the initiation and elongation
of neuritic processes, a dramatic phenotypic change which
accompanies neuronal-specific differentiation. The fused PC12
cell model (22, 51) was invaluable to our studies because the
large fused cells remain unscathed after micropipette im-
Figure 4. Inhibition of FGF-
induced neurite outgrowth by
microinjection of fused PC12
cells with anti-Src 327or anti-
Ras Y13-259. (A)Fused PC12
cells were treated with 10 ng/
ml bFGF for 76 handthen mi-
croinjected with control anti-
bodies (control) or with anti-
Src 327 (anti-src). The cells
were incubated with bFGF for
an additional 18 h and were
then scored for neurites, and
the data plotted as in Fig. 1.
(B) Fused PC12 cells were
treated with 10 ng/ml bFGF
for 30 h, and then microin-
jected with control antibodies
(control) or with anti-Ras Y13-
259 (anti-ras) . The cells were
incubated with bFGF for an
317
￿
additional 24 h and were then
scored for neurites, and the
data plotted as in Fig. 1. In
both A and B, each bar plots
thepercentage of cells bearing
neurites, and the number of
cells counted after each treat-
none
￿
control
￿
anti-ras
￿
ment is shownabove each bar.
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palement and because neurite outgrowth is rapidly inducible
by appropriate agents. A previous study which showed that
microinjection of a neutralizing mAb to Ras blocks NGF-
induced neurite growth provided evidence that a Ras protein
is essential for NGF-induced neurite outgrowth (21).
Our experiments provide two novel findings: (a) Neutral-
ization of either cellular Src or Ras actions by microinjection
of corresponding mAbs interrupts transduction of the NGF
and the FGF signals that induce neurite outgrowth; and (b)
Neutralization of Ras action blocks v-src-induced neurite
outgrowth; however, neutralization of Src action does not
block ryas oncogene-induced neurite outgrowth. Based on
these findings, we propose that pp6O`-s- and p21-s proteins
are integral components ofa signal transduction cascade that
is initiated by occupied NGF or FGF receptors to induce
neurite outgrowth . Since both the NGF and FGF receptors
possess tyrosine kinase activity, these results establish a
physiological role for the pp60- tyrosine kinase in events
initiated by receptor tyrosine kinases in PC12 cells. The sim-
plest model which can accommodate all the available evi-
dence involves the following sequence of actions: neuronal
growth factor/receptor - pp60- - p21°-- - neurites. The
ability ofantibodies to either the Src or Ras proteins to cause
retraction of established neurites indicates that these compo-
nents are constitutively required to transduce the NGF and
FGF responses. This is consistent withthe continual require-
ment of NGF or FGF in inducing neurite growth. Implicit
in our model is the assumption that the transforming Src
and Ras oncogene proteins faithfully mimic their physiologi-
cally activated cellular counterparts in inducing neurite out-
growth.
The identity of the antibody target is critical in the in-
terpretation of these experiments. Anti-Ras Y13-259, which
816was raised against p21,--s (15), recognizes an epitope (37,
60) on viral and cellular Ras proteins including H-Ras,
K-Ras, and N-Ras proteins (4), but does not recognize R-Ras
proteins (F. McCormick, personal communication) . Analy-
sis of deduced amino acid sequences (57) and experimental
evidence (F McCormick, personal communication) show
that Ras-related proteins in the Rap, Ral, Rho, and Rab fami-
lies of GTP-binding proteins do not react with anti-Ras Y13-
259. Thus, it is likely that one or more members of the Ras
protein family mediates growth factor-induced neurite out-
growth. In further support of this role for p21c-, expres-
sion of a dominantly acting, inhibitory ras mutant blocks
neurite outgrowth induced by NGF and FGF (64), and by
pp60-rc (shown herein).
Our identification of pp60c-s- as the specific antigen neu-
tralized by anti-Src microinjection is more certain. Anti-Src
327 appears to recognize only Src proteins, since no detect-
able kinase activity was observed in anti-Src 327-derived
immunoprecipitates from lysates of fibroblasts and brain tis-
sue derived from mice homozygous for a c-src null mutation
(62; J. Thomas and J. Brugge, unpublished data). It is con-
ceivable that a low-affinity interaction of anti-Src 327 with
a Src-related protein could be responsible for the inhibition
ofneurite outgrowth observed here; however the observation
that a second antibody, anti-Src (2-17), which is specific for
an amino acid sequence unique to pp60c-s- (8), also in-
hibited NGF- and FGF-induced neurites, clearly establishes
a role for pp60-- in this process. The mechanism by which
anti-Src (2-17) and anti-Src 327 neutralize Src functions is
unknown. Binding ofthe antibodies to the myristylated amino
terminus or SH3 regions, respectively, may directly prevent
functional interactions at these domains, or the loss of func-
tion may result from a more generalized steric interference.
The assignment of the anti-Src 327 epitope to the SH3 do-
main (amino acid residues 88-137) of the Src protein (55)
is based on antibody recognition of numerous mutant vari-
ants of the Src protein (52 ; L. Fox, C. Seidel-Dugan, S.
Thomas, and J. Brugge, unpublished data; and H . Hirai and
H. E. Varmus, unpublished data).
The observations by ourselves and others, indicate that
pp60- and p21- are essential components of a complex
signal transduction pathway used by NGF to cause neurite
outgrowth in PC12 cells. The pathway used by NGF recruits
avariety of second messengers which lead to numerous post-
translational modifications and gene inductions to elicit its
effects (for review see reference 23). Based on our functional
assessments ofthese molecules, we have been able to order
pp60-s- and p21- activities within this pathway to neurite
growth. However, Src and Ras proteins may not be involved
in transducing all actions of NGF For example, expression
of v-src (54) or of a ras oncogene (29) does not mimic the
NGF-induced increase in functional Na+ channels in PC12
cells. The precise relationship between pp60°-- and p21-s
functions, and the second messenger systems and other com-
ponents of the signal transduction pathway which mediate
neuronal growth factor actions, remains to be elucidated. We
have proposed a simple linear cascade of Src and Ras ac-
tions in NGF and FGF actions, however, another interesting,
though more complex model deserves attention. Receptor
tyrosine kinases may activate Ras through Src-dependent as
well as Src-independent pathways. In this model, the abso-
lute requirement for Src may depend on the extent of recep-
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for activation, which can be limited by ligand concentration
or receptor number (as is the case for NGF and FGF recep-
tors in PC12 cells) .
The ability of oncogenic variants of Src or Ras to induce
both rapid and long-term events required for neurite out-
growth in the absence of neuronal growth factors suggests
that cellular homologues of these proteins may act at an early
stage in the signal transduction cascade. In addition, both
pp60-rc and oncogenic Ras are able to "prime" (19) neurite
growth induced by NGF, suggesting that NGF and these on-
cogenes use common pathways to elicit neurite growth, in-
volving gene transcription (65). In support ofthis suggestion,
pp60,
s- (54, 65), and oncogenic Ras (20, 58; G. DArcan-
gelo, R. Armstrong, and S. Halegoua, unpublished data)
proteins induce rapid (immediate-early) as well as long-
term expression ofNGF-responsive genes. Furthermore, ex-
pression of a dominant inhibitory ras mutant blocks specific
gene expression induced by NGF (64) . Lastly, anti-Src does
not block ras oncogene-induced neurite growth, and neither
anti-Src nor anti-Ras blockneuritelike process outgrowth in-
duced by cAMP, suggesting that the Src and Ras proteins are
not essential for process outgrowth per se. Based on all of
the above considerations, we propose that stimulation ofthe
Src - Ras cascade is an early event in the NGF and FGF
signal transduction pathway, perhaps even directly interact-
ing with the growth factor receptors themselves.
Src and Ras may bothbe components ofprotein assemblies
which possibly include the NGF and FGF receptors. Protein
complexes have been described, for example, for the PDGF
receptor (a tyrosine kinase), which associates with the Src,
Fyn, and Yes tyrosine kinases (36), the Ras-GTPase activat-
ing protein (GAP), phospholipase C--y, and 3' phosphatidyl-
inositol kinase (30, 33), and Raf-1 kinase (48), possibly to
form a multimeric complex . It will be of interest to deter-
mine if such protein associations exist for the NGF receptor,
and for the FGF receptor, both ofwhich possess tyrosine ki-
nase activity (26, 31, 32, 34, 38) .
Our results from studies on NGF- and FGF-induced neu-
rite outgrowth have several general implications. First, given
the structural differences between NGF, FGF, and their
receptors, the demonstration of pp60°-
src and p21- as es-
sential components of both NGF- and FGF-induced neurite
outgrowth suggests that neuronal growth factor signal trans-
duction may in general involve a cascade ofSrc- and Ras-like
actions. Consistent with this general scheme is the finding
that oncogenic Ras can alleviate the survival requirements of
various cultured neurons for several neuronal growth factors
(6) . Second, that the FGF receptor, Src and Ras can each
mediate mitogenesis in one cell type and neuronal differenti-
ation in another, suggests that similar mechanisms may un-
derlie these diverse processes. We suggest that cascades
similar to Src - Ras may represent a functional cassette used
in the signal transduction pathways for growth factors and
other ligands in a wide variety of physiological processes in
different cell types. This idea is further supported by the Ras
requirement in serum- and growth factor-induced mitogene-
sis (7, 49) in insulin-induced oocyte maturation (11, 35), and
in developmental induction in Caenorhabditus elegans (2) .
The involvement of Src, or other non-receptor tyrosine ki-
nases in such processes remains to be elucidated. Third, that
the NGF and FGF receptors, which both possess tyrosine ki-
nase activity, recruit the action ofa non-receptor tyrosine ki-
817nase, Src, suggests that such a sequence of tyrosine kinase
activities may occur in both the mitogenic and in the differ-
entiating actions of these growth factors and possibly those
of other growth factors having tyrosine kinase receptors.
Determining the relationships between Src and Ras in
growth control and oncogenesis has long been an active pur-
suit. Vsrc-induced mitogenesis requires a Ras-like action
(7, 61), leaving undetermined the arrangement of Src and Ras
actions in serial versus parallel pathways. Biochemical evi-
dence compatiblewith a linear, sequential model for Src and
Ras actions shows that the Ras GTPase-activating protein,
GAP (68), is a substrate for pp60°-src as well as for tyrosine
kinase growth factor receptors (12, 30, 47). Although the
regulatory interactions between Ras and GAP are not fully
understood (24, 44), phosphorylation ofGAP by tyrosine ki-
nases may be a mechanism by which Ras activity is con-
trolled in vivo. Assuming that mitogenesis and neuronal
differentiation are similarly induced by these oncogenes, we
have further extended the functional relationship between
Src and Ras activities in these processes by demonstrating
a sequential pathway in which Ras action lies downstream of
Src action. The possible intermediates in such a cascade re-
main to be elucidated. ,
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